Comparison of the effect of Prostanen with tamsulosin in the treatment of benign prostatic hyperplasia

Comparison of the effect of Prostanen soft capsule with tamsulosin in the treatment of patients with benign prostatic hyperplasia ( Single blind randomised Clinical Trial)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20081011001323N32

Enrollment

128

Registered

2025-06-08

Start date

2025-04-05

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia. N40

Interventions

Intervention 1: Intervention group: Every night, one soft prostanen capsule was prescribed with a glass of water for two months. Intervention 2: Control group: every night, one 0.4 mg oral capsule of

Eligibility

Sex/Gender

Male

Age

50 Years to 85 Years

Inclusion criteria

Inclusion criteria: Men older than 45 years old suffering from Benign Prostatic Hyperplasia (BPH) candidate for medical treatment with International Prostatic Symptom Score (IPSS) less than 20

Exclusion criteria

Exclusion criteria: Men with benign prostatic hyperplasia with azotemia Patients with active urinary tract infection Patients with history of herbal or medical allergy Patients suspicions for prostatic cancer

Design outcomes

Primary

Measure	Time frame
Change of obstructive and irritative symptoms of prostatic hyperplasia. Timepoint: At the start of study and two month later. Method of measurement: Using international prostatic symptom score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSadrollah Mehrabi

Yasouj University of Medical Sciences

sadrollahm@yahoo.com+98 74 3322 1812

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026